These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 25450307)

  • 1. Presynaptic effects of levodopa and their possible role in dyskinesia.
    Mosharov EV; Borgkvist A; Sulzer D
    Mov Disord; 2015 Jan; 30(1):45-53. PubMed ID: 25450307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
    Carta M; Bezard E
    Neuroscience; 2011 Dec; 198():245-51. PubMed ID: 21840375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the serotonin system in L-dopa-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S154-8. PubMed ID: 18579429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
    Cenci MA
    Trends Neurosci; 2007 May; 30(5):236-43. PubMed ID: 17400300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4. PubMed ID: 10762137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic intermittent L-DOPA treatment induces changes in dopamine release.
    Lundblad M; af Bjerkén S; Cenci MA; Pomerleau F; Gerhardt GA; Strömberg I
    J Neurochem; 2009 Feb; 108(4):998-1008. PubMed ID: 19196428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
    Cenci MA; Lundblad M
    J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Sahin G; Thompson LH; Lavisse S; Ozgur M; Rbah-Vidal L; Dollé F; Hantraye P; Kirik D
    PLoS One; 2014; 9(3):e90759. PubMed ID: 24614598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
    Calabresi P; Di Filippo M; Ghiglieri V; Tambasco N; Picconi B
    Lancet Neurol; 2010 Nov; 9(11):1106-17. PubMed ID: 20880751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
    Rylander D; Parent M; O'Sullivan SS; Dovero S; Lees AJ; Bezard E; Descarries L; Cenci MA
    Ann Neurol; 2010 Nov; 68(5):619-28. PubMed ID: 20882603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical physiology of dopa dyskinesia.
    Hallett M
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
    Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
    Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M; Carlsson T; Kirik D; Björklund A
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.